Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- UAL +5%, BKU +4.8%, FHN +4.7%, OMC +2.8%, HWC +2.5%, GAU +2.1%
Other news:
- VNDA +22% (Future Pak confirms proposal to acquire Vanda Pharmaceuticals for $7.25 to $7.75/share in cash)
- GENE +5% (established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand)
- ATHE +4.9% (announced that three posters were presented at the American Academy of Neurology)
- ATAI +4.7% (Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology)
- RIO +3.4% (reports Q1 production)
- VALE +3.3% (reports Q1 production and sales)
- CDNA +2.7% (names new CEO)
- BCRX +2.6% (receives approval for ORLADEYO by the Brazilian Health Regulatory Agency)
- BVN +2.3% (Announces First Quarter 2024 Results for Production and Volume Sold per Metal)
- ALVO +2.1% (FDA approves Selarsdi injection as a biosimilar to Stelara)
- TCRX +1.8% (prices upsized $150 million public offering)
- AAL +1.8% (in sympathy with UAL earnings)
- DAL +1.7% (in sympathy with UAL earnings)
- XPEV +1.7% (XPeng and the Volkswagen Group (VWAGY) announce entry into the framework agreement on E/E Architecture technical collaboration)
- JBLU +1.5% (in sympathy with UAL earnings)
- GNL +1.4% (announces $462 million of dispositions closed or under agreement¹ as part of strategic disposition plan)
- TEVA +1% (FDA approves Selarsdi injection as a biosimilar to Stelara)